Genmab A/S GMAB 深 沪
等待开盘 12-18 09:30:00 美东时间
31.71
+0.360
+1.15%
华盛通- 最 高31.9101
- 今 开31.57
- 成交量 108.19万股
- 最 低 31.57
- 昨 收 31.35
- 总市值 195.33亿
- 52周最高 33.65
- 市盈率 静 18.02
- 换手率 0.18%
- 52周最低 17.235
- 委 比 53.55%
- 总股本 6.16亿
- 历史最高 49.07
- 量 比 0.62
- 振 幅 1.08%
- 历史最低 16.24
- 每 手 1
- 风险率 4.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
BioNTech完成对CureVac的收购，收购比例达86.75%，剩余股份将于2026年1月通过强制收购完成。此次收购将增强BioNTech在mRNA设计、递送配方和生产方面的能力。CureVac将继续运营，BioNTech将进行战略分析以确定未来架构。
今天 09:45
Genmab’s Rina-S: New Study Targets Lung Cancer with Innovative Treatment
Genmab (Otc) ($GMAB) announced an update on their ongoing clinical study. Genma...
今天 00:31
Merus Acquired by Genmab, Leadership Changes Announced
An announcement from Merus ( ($MRUS) ) is now available. On December 11, 2025, ...
12-12 21:18
Bristol Myers' Cancer Breakthrough Breyanzi Just Won Its Fifth FDA Approval
FDA approves Breyanzi, a CAR T cell therapy for relapsed or refractory marginal zone lymphoma. It has a high response rate.
12-05 21:36
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
BioNTech announced that the minimum condition for its exchange offer of CureVac shares has been met, with approximately 81.74% of CureVac's outstanding shares tendered. The subsequent offering period has begun and will expire on December 18, 2025. BioNTech will now deliver ADSs or cash to tendering CureVac shareholders, completing the transaction. Non-tendering holders will receive ADSs through the post-offer reorganization, subject to a 15% Dutc...
12-03 14:01
MHRA Approves Tisotumab Vedotin For The Treatment Of Cervical Cancer
https://www.gov.uk/government/news/mhra-approves-tisotumab-vedotin-for-the-treatment-of-cervical-cancer
12-02 23:29
美股盘前 | 存储概念股盘前普涨，SanDisk涨超4%；有机构称球存储芯片短缺加剧
存储概念股盘前普涨，SanDisk涨超4%，美光科技涨超3%，西部数据涨近2%；有机构称全球存储芯片短缺加剧，存储芯片价格预计再涨50%>>
11-28 17:33
Genmab A/S Updates Articles of Association for Financial Flexibility
The latest update is out from Genmab ( ($GMAB) ). On November 26, 2025, Genmab ...
11-26 20:28
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
BioNTech announced the approval of its exchange offer for all outstanding shares of CureVac at an extraordinary general meeting held on November 25, 2025. Over 99.16% of CureVac shareholders voted in favor of the proposals. The offer is set to expire at 9:00 am Eastern Time on December 3, 2025, with shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, 2025. The exchange ratio is 0.05363 of a BioNTech ADS per CureVac ...
11-26 12:30
Genmab Grants Stock Units and Warrants to Employees
Genmab ( ($GMAB) ) has provided an update. On November 20, 2025, Genmab A/S ann...
11-21 04:47
